| Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma S Bedrose, KC Miller, L Altameemi, MS Ali, S Nassar, N Garg, M Daher, ... Journal for immunotherapy of cancer 8 (2), 2020 | 41 | 2020 |
| Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma KC Miller, PC Johnson, JS Abramson, JD Soumerai, AJ Yee, ... Blood Cancer Journal 12 (10), 146, 2022 | 37 | 2022 |
| Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma VG Ramakrishnan, KC Miller, EP Macon, TK Kimlinger, J Haug, S Kumar, ... Haematologica 104 (10), 2061, 2019 | 33 | 2019 |
| Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma KC Miller, JP Marinelli, JJ Van Gompel, MJ Link, JR Janus, RL Foote, ... Head & neck 41 (5), 1335-1341, 2019 | 30 | 2019 |
| Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells P Karschnia, KC Miller, AJ Yee, K Rejeski, PC Johnson, N Raje, ... Blood 142 (14), 1243-1248, 2023 | 28 | 2023 |
| Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis BK Ragon, MV Shah, A D’Souza, N Estrada-Merly, L Gowda, G George, ... Blood advances 7 (12), 2746-2757, 2023 | 22 | 2023 |
| The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma KC Miller, MA Gertz, FK Buadi, SR Hayman, MQ Lacy, AA Dispenzieri, ... Bone marrow transplantation 54 (12), 2039-2050, 2019 | 18 | 2019 |
| Induction therapy prior to surgical resection for patients presenting with locally advanced esthesioneuroblastoma KC Miller, JP Marinelli, JR Janus, AV Chintakuntlawar, RL Foote, MJ Link, ... Journal of Neurological Surgery Part B: Skull Base 82 (S 03), e131-e137, 2021 | 16 | 2021 |
| Salvage therapy with multikinase inhibitors and immunotherapy in advanced adrenal cortical carcinoma KC Miller, AV Chintakuntlawar, C Hilger, I Bancos, JC Morris, M Ryder, ... Journal of the Endocrine Society 4 (7), bvaa069, 2020 | 16 | 2020 |
| Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients KC Miller, A Al-Kali, MV Shah, WJ Hogan, MA Elliott, KH Begna, N Gangat, ... Leukemia & Lymphoma 60 (4), 990-999, 2019 | 15 | 2019 |
| Molecular-driven therapy in advanced thyroid cancer KC Miller, AV Chintakuntlawar Current treatment options in oncology 22 (3), 24, 2021 | 14 | 2021 |
| Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma KC Miller, MA Gertz, FK Buadi, SR Hayman, RC Wolf, MQ Lacy, ... Bone marrow transplantation 54 (4), 587-594, 2019 | 13 | 2019 |
| Impact of novel targeted therapies and cytogenetic risk groups on outcome after allogeneic transplantation for adult ALL ZHA Rahman, MG Heckman, K Miller, H Alkhateeb, MS Patnaik, ... Transplantation and Cellular Therapy 27 (2), 165. e1-165. e11, 2021 | 12 | 2021 |
| Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis O Pasvolsky, M Yeshurun, R Fraser, N Estrada-Merly, U Rozovski, ... Bone marrow transplantation 57 (1), 31-37, 2022 | 10 | 2022 |
| Comparative study of therapyrelated and de novo adult bcell acute lymphoblastic leukaemia ZH Abdel Rahman, RD Parrondo, MG Heckman, M Wieczorek, KC Miller, ... British journal of haematology 196 (4), 963-968, 2022 | 8 | 2022 |
| Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics ZHA Rahman, KC Miller, H Jabbour, Y Alkhatib, V Donthireddy Hematology/oncology and stem cell therapy, 2021 | 3 | 2021 |
| Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma KC Miller, H Hashmi, S Rajeeve Frontiers in Oncology 14, 1398902, 2024 | 1 | 2024 |
| Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure KC Miller, AC Hall, A Cohen-Bucay, YB Chen Leukemia Research Reports 17, 100302, 2022 | 1 | 2022 |
| P-011 Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma B Costa, S Rajeeve, E Jurgens, N Nishimura, T Farzana, R Firestone, ... Clinical Lymphoma Myeloma and Leukemia 24, S46, 2024 | | 2024 |
| P-095 Impact of Granulocyte Colony-Stimulating Factor Exposure on Cytokine Release Syndrome During Bispecific Antibody Initiation in Relapsed/Refractory Multiple Myeloma A Wang, T Shekarkhand, A Derkach, D Nemirovsky, C Tan, I Hamadeh, ... Clinical Lymphoma Myeloma and Leukemia 24, S97, 2024 | | 2024 |
